Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review)
- Authors:
- Sara Fathallah
- Ahmed Abdellatif
- Mona Kamal Saadeldin
-
Affiliations: Biotechnology Program, School of Science and Engineering, American University in Cairo, New Cairo 11835, Egypt - Published online on: August 17, 2023 https://doi.org/10.3892/mi.2023.102
- Article Number: 42
-
Copyright : © Fathallah et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
|
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, et al: Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler J. 26:1816–1821. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chiurchiù V, van der Stelt M, Centonze D and Maccarrone M: The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Prog Neurobiol. 160:82–100. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ghasemi N, Razavi S and Nikzad E: Multiple sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 19:1–10. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Nishanth K, Tariq E, Nzvere FP, Miqdad M and Cancarevic I: Role of smoking in the pathogenesis of multiple sclerosis: A review article. Cureus. 12(e9564)2020.PubMed/NCBI View Article : Google Scholar | |
|
Pfeuffer S, Kerschke L, Ruck T, Rolfes L, Pawlitzki M, Albrecht P, Wiendl H and Meuth SG: Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis. Ther Adv Neurol Disord. 14(1756286421997372)2021.PubMed/NCBI View Article : Google Scholar | |
|
Manouchehrinia A, Tench CR, Maxted J, Bibani RH, Britton J and Constantinescu CS: Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain. 2013;136(Pt 7):2298–2304. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Stoiloudis P, Kesidou E, Bakirtzis C, Sintila SA, Konstantinidou N, Boziki M and Grigoriadis N: The role of diet and interventions on multiple sclerosis: A review. Nutrients. 14(1150)2022.PubMed/NCBI View Article : Google Scholar | |
|
Sameer AS and Nissar S: Toll-Like receptors (TLRs): Structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility. Biomed Res Int. 2021(1157023)2021.PubMed/NCBI View Article : Google Scholar | |
|
Takeda K, Kaisho T and Akira S: Toll-like receptors. Annu Rev Immunol. 21:335–376. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B and Vartanian T: Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc Natl Acad Sci USA. 107:11555–11560. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Liu Y, Yin H, Zhao M and Lu Q: TLR2 and TLR4 in autoimmune diseases: A comprehensive review. Clin Rev Allergy Immunol. 47:136–147. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Shaw PJ, Barr MJ, Lukens JR, McGargill MA, Chi H, Mak TW and Kanneganti TD: Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity. Immunity. 34:75–84. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Constantinescu CS, Farooqi N, O'Brien K and Gran B: Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 164:1079–1106. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Mahmoudi M, Rastin M, Kazemi Arababadi M, Anaeigoudari A and Nosratabadi R: Enhancing the efficacy of Hypericum perforatum in the treatment of an experimental model of multiple sclerosis using gold nanoparticles: An in vivo study. Avicenna J Phytomedicine. 12:325–336. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Andersson Å, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, Wallström E, Lobell A, Brundin L, Lassmann H and Harris RA: Pivotal Advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 84:1248–1255. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Reynolds JM, Martinez GJ, Chung Y and Dong C: Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci USA. 109:13064–13069. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Bustamante MF, Fissolo N, Río J, Espejo C, Costa C, Mansilla MJ, Lizasoain I, Moro MA, Carmen Edo M, Montalban X and Comabella M: Implication of the toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis. Ann Neurol. 70:634–645. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Zheng C, Chen J, Chu F, Zhu J and Jin T: Inflammatory Role of TLR-MyD88 signaling in multiple sclerosis. Front Mol Neurosci. 12(314)2020.PubMed/NCBI View Article : Google Scholar | |
|
Marta M, Meier UC and Lobell A: Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun Rev. 8:506–509. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Deguine J and Barton GM: MyD88: A central player in innate immune signaling. F1000Prime Rep. 6(97)2014.PubMed/NCBI View Article : Google Scholar | |
|
Lee YK, Kang M and Choi EY: TLR/MyD88-mediated innate immunity in intestinal graft-versus-host disease. Immune Netw. 17:144–151. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Lai CY, Su YW, Lin KI, Hsu LC and Chuang TH: Natural modulators of endosomal toll-like receptor-mediated psoriatic skin inflammation. J Immunol Res. 2017(7807313)2017.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Wang T, Liu X, Ji Z, Men Y, Du M, Ding C, Wu Y, Liu X and Kang Q: Antitumor and immunomodulatory effects of recombinant fusion protein rMBP-NAP through TLR-2 dependent mechanism in tumor bearing mice. Int Immunopharmacol. 2015. 29:876–883. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Gambuzza M, Licata N, Palella E, Celi D, Foti Cuzzola V, Italiano D, Marino S and Bramanti P: Targeting toll-like receptors: Emerging therapeutics for multiple sclerosis management. J Neuroimmunol. 239:1–12. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Arslan F, Houtgraaf JH, Keogh B, Kazemi K, De Jong R, McCormack WJ, O'Neill LA, McGuirk P, Timmers L, Smeets MB, et al: Treatment with OPN-305, a humanized anti-toll-like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 5:279–287. 2012.PubMed/NCBI View Article : Google Scholar | |
|
O'Neill LAJ, Hennessy EJ and Parker AE: Targeting Toll-like receptors: Emerging therapeutics? Nat Rev Drug Discov. 9:293–307. 2010. | |
|
Church JS, Milich LM, Lerch JK, Popovich PG and McTigue DM: E6020, a synthetic TLR4 agonist, accelerates myelin debris clearance, Schwann cell infiltration, and remyelination in the rat spinal cord. Glia. 65:883–899. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Gooshe M, Abdolghaffari AH, Gambuzza ME and Rezaei N: The role of toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes. Rev Neurosci. 25:713–739. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Baig MS, Roy A, Saqib U, Rajpoot S, Srivastava M, Naim A, Liu D, Saluja R, Faisal SM, Pan Q, et al: Repurposing thioridazine (TDZ) as an anti-inflammatory agent. Sci Rep. 8(12471)2018.PubMed/NCBI View Article : Google Scholar | |
|
Bonetti B, Stegagno C, Cannella B, Rizzuto N, Moretto G and Raine CS: Activation of NF-κB and c-jun transcription factors in multiple sclerosis lesions: Implications for oligodendrocyte pathology. Am J Pathol. 155:1433–1438. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Gveric D, Kaltschmidt C, Cuzner ML and Newcombe J: Transcription Factor NF-kappaB and Inhibitor IkappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropathol Exp Neurol. 57:168–178. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Housley WJ, Fernandez SD, Vera K, Murikinati SR, Grutzendler J, Cuerdon N, Glick L, De Jager PL, Mitrovic M, Cotsapas C and Hafler DA: Genetic variants associated with autoimmunity drive NFκB signaling and responses to inflammatory stimuli. Sci Transl Med. 7(291ra93)2015.PubMed/NCBI View Article : Google Scholar | |
|
Arellano G, Acuña E, Reyes LI, Ottum PA, De Sarno P, Villarroel L, Ciampi E, Uribe-San Martín R, Cárcamo C and Naves R: Th1 and Th17 cells and associated cytokines discriminate among clinically isolated syndrome and multiple sclerosis phenotypes. Front Immunol. 8(753)2017.PubMed/NCBI View Article : Google Scholar | |
|
Becher B and Segal BM: T H17 cytokines in autoimmune neuro-inflammation. Curr Opin Immunol. 23:707–712. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Segal BM, Dwyer BK and Shevach EM: An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med. 187:537–546. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Panitch HS, Hirsch RL, Haley AS and Johnson KP: Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1:893–895. 1987.PubMed/NCBI View Article : Google Scholar | |
|
Nicoletti F, Patti F, Cocuzza C, Zaccone P, Nicoletti A, Di Marco R and Reggio A: Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol. 70:87–90. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Alboni S, Cervia D, Sugama S and Conti B: Interleukin 18 in the CNS. J Neuroinflammation. 7(9)2010.PubMed/NCBI View Article : Google Scholar | |
|
Weinstock JV, Blum A, Metwali A, Elliott D and Arsenescu R: IL-18 and IL-12 signal through the NF-kappa B pathway to induce NK-1R expression on T cells. J Immunol. 170:5003–5007. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Karni A, Koldzic DN, Bharanidharan P, Khoury SJ and Weiner HL: IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol. 125:134–140. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Sica A, Dorman L, Viggiano V, Cippitelli M, Ghosh P, Rice N and Young HA: Interaction of NF-kappaB and NFAT with the interferon-gamma promoter. J Biol Chem. 272:30412–30420. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Nicoletti F, Di Marco R, Mangano K, Patti F, Reggio E, Nicoletti A, Bendtzen K and Reggio A: Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology. 57:342–344. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Wildbaum G, Youssef S, Grabie N and Karin N: Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J Immunol. 161:6368–6374. 1998.PubMed/NCBI | |
|
Losy J and Niezgoda A: IL-18 in patients with multiple sclerosis. Acta Neurol Scand. 104:171–173. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Sun SC, Chang JH and Jin J: Regulation of nuclear factor-κB in autoimmunity. Trends Immunol. 34:282–289. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, et al: T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 28:29–39. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM and Fugger L: Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 172:146–155. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P and Novelli F: T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 65:499–509. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Muls N, Jnaoui K, Dang HA, Wauters A, van Snick J, Sindic CJ and van Pesch V: Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. J Neuroimmunol. 243:73–80. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Sutton C, Brereton C, Keogh B, Mills KH and Lavelle EC: A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 203:1685–1691. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F and Drulovic J: The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol. 207:101–106. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Badovinac V, Mostarica-Stojković M, Dinarello CA and Stošić-Grujičić S: Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol. 85:87–95. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Xiao Y, Jin J, Chang M, Nakaya M, Hu H, Zou Q, Zhou X, Brittain GC, Cheng X and Sun SC: TPL2 mediates autoimmune inflammation through activation of the TAK1 axis of IL-17 signaling. J Exp Med. 211:1689–1702. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K and Iwakura Y: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 177:566–573. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Haak S, Croxford AL, Kreymborg K, Heppner FL, Pouly S, Becher B and Waisman A: IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest. 119:61–69. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Sonderegger I, Kisielow J, Meier R, King C and Kopf M: IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur J Immunol. 38:1833–1838. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, Heppner FL, Renauld JC and Becher B: IL-22 is expressed by Th17 Cells in an IL-23-Dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol. 179:8098–8104. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Leibowitz SM and Yan J: NF-κB pathways in the pathogenesis of multiple sclerosis and the therapeutic implications. Front Mol Neurosci. 9(84)2016.PubMed/NCBI View Article : Google Scholar | |
|
Lebman DA and Spiegel S: Cross-talk at the crossroads of sphingosine-1-phosphate, growth factors, and cytokine signaling. J Lipid Res. 49:1388–1394. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Colombo E, Di Dario M, Capitolo E, Chaabane L, Newcombe J, Martino G and Farina C: Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann Neurol. 76:325–337. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Spiegel S and Milstien S: The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 11:403–415. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Takabe K, Paugh SW, Milstien S and Spiegel S: Inside-out signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol Rev. 60:181–195. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Kim JH, Kim JH, Song WK, Kim JH and Chun JS: Sphingosine 1-phosphate activates Erk-1/-2 by transactivating epidermal growth factor receptor in Rat-2 cells. IUBMB Life. 50:119–124. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Napolitano G and Karin M: Sphingolipids: The Oil on the TRAFire that promotes inflammation. Sci Signal. 3(pe34)2010.PubMed/NCBI View Article : Google Scholar | |
|
Yopp AC, Ochando JC, Mao M, Ledgerwood L, Ding Y and Bromberg JS: Sphingosine 1-Phosphate receptors regulate chemokine-driven transendothelial migration of lymph node but not splenic T cells. J Immunol. 175:2913–2924. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Honig SM, Fu S, Mao X, Yopp A, Gunn MD, Randolph GJ and Bromberg JS: FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest. 111:627–637. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Pham TH, Okada T, Matloubian M, Lo CG and Cyster JG: S1P1 Receptor signaling overrides retention mediated by G alpha i-Coupled receptors to promote T cell egress. Immunity. 28:122–133. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Bridel C and Lalive PH: Update on multiple sclerosis treatments. Swiss Med Wkly. 144(w14012)2014.PubMed/NCBI View Article : Google Scholar | |
|
Warnke C, Zu Hörste GM, Hartung HP, Stüve O and Kieseier BC: Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 5:333–340. 2009.PubMed/NCBI | |
|
Manna SK and Aggarwal BB: Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol. 162:2095–2102. 1999.PubMed/NCBI | |
|
Cua DJ and Tato CM: Innate IL-17-producing cells: The sentinels of the immune system. Nat Rev Immunol. 10:479–489. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Infante-Duarte C, Horton HF, Byrne MC and Kamradt T: Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol. 165:6107–6115. 2000.PubMed/NCBI View Article : Google Scholar | |
|
McGeachy MJ, Cua DJ and Gaffen SL: The IL-17 family of cytokines in health and disease. Immunity. 50:892–906. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kolbinger F, Huppertz C, Mir A and Padova F: IL-17A and multiple sclerosis: Signaling pathways, producing cells and target cells in the central nervous system. Curr Drug Targets. 17:1882–1893. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M, Zarrilli R, Imeneo M and Pallone F: Up-Regulation of IL-17 is associated with bioactive IL-8 expression in helicobacter pylori-infected human gastric mucosa. J Immunol. 165:5332–5337. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Kostic M, Dzopalic T, Zivanovic S, Zivkovic N, Cvetanovic A, Stojanovic I, Vojinovic S, Marjanovic G, Savic V and Colic M: IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis. Scand J Immunol. 79:181–186. 2014.PubMed/NCBI View Article : Google Scholar | |
|
González H and Pacheco R: T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation. 11(201)2014.PubMed/NCBI View Article : Google Scholar | |
|
Gu C, Wu L and Li X: IL-17 family: Cytokines, receptors and signaling. Cytokine. 64:477–485. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Saadeldin MK: Highlights from the ‘Noncoding RNA world : From Mechanism to Therapy’ conference. wasj. 3(64)2021. | |
|
Jin M, Akgün K, Ziemssen T, Kipp M, Günther R and Hermann A: Interleukin-17 and th17 lymphocytes directly impair motoneuron survival of wildtype and FUS-ALS mutant human iPSCs. Int J Mol Sci. 22(8042)2021.PubMed/NCBI View Article : Google Scholar | |
|
Ransohoff RM: How neuroinflammation contributes to neurodegeneration. Science. 353:777–783. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zimmermann J, Krauthausen M, Hofer MJ, Heneka MT, Campbell IL and Müller M: CNS-targeted production of IL-17A induces glial activation, microvascular pathology and enhances the neuroinflammatory response to systemic endotoxemia. PLoS One. 8(e57307)2013.PubMed/NCBI View Article : Google Scholar | |
|
Rodgers JM, Robinson AP, Rosler ES, Lariosa-Willingham K, Persons RE, Dugas JC and Miller SD: IL-17A activates ERK1/2 and enhances differentiation of oligodendrocyte progenitor cells. Glia. 63:768–779. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Chen J, Liu X and Zhong Y: Interleukin-17A: The key cytokine in neurodegenerative diseases. Front Aging Neurosci. 12(566922)2020.PubMed/NCBI View Article : Google Scholar | |
|
Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M and Nagarkatti PS: Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol. 72:1508–1521. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Wang J, Chen F, Zheng P, Deng W, Yuan J, Peng B, Wang R, Liu W, Zhao H, Wang Y and Wu G: Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice. Exp Neurol. 236:79–87. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Zhao X, Kan Q, Zhu L and Zhang GX: Matrine suppresses production of IL-23/IL-17 and ameliorates experimental autoimmune encephalomyelitis. Am J Chin Med. 39:933–941. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Sanadgol N, Golab F, Tashakkor Z, Taki N, Moradi Kouchi S, Mostafaie A, Mehdizadeh M, Abdollahi M, Taghizadeh G and Sharifzadeh M: Neuroprotective effects of ellagic acid on cuprizone-induced acute demyelination through limitation of microgliosis, adjustment of CXCL12/IL-17/IL-11 axis and restriction of mature oligodendrocytes apoptosis. Pharm Biol. 55:1679–1687. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kostic M, Zivkovic N, Cvetanovic A, Stojanovic I and Colic M: IL-17 signalling in astrocytes promotes glutamate excitotoxicity: Indications for the link between inflammatory and neurodegenerative events in multiple sclerosis. Mult Scler Relat Disord. 11:12–17. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, et al: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 8:500–508. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Das Sarma J, Ciric B, Marek R, Sadhukhan S, Caruso ML, Shafagh J, Fitzgerald DC, Shindler KS and Rostami A: Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J Neuroinflammation. 6(14)2009.PubMed/NCBI View Article : Google Scholar | |
|
Liu G, Guo J, Liu J, Wang Z and Liang D: Toll-like receptor signaling directly increases functional IL-17RA expression in neuroglial cells. Clin Immunol. 154:127–140. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Brelstaff J, Tolkovsky AM, Ghetti B, Goedert M and Spillantini MG: Living neurons with tau filaments aberrantly expose phosphatidylserine and are phagocytosed by microglia. Cell Rep. 24:1939–1948.e4. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Qin Y, Garrison BS, Ma W, Wang R, Jiang A, Li J, Mistry M, Bronson RT, Santoro D, Franco C, et al: A milieu molecule for TGF-β Required for microglia function in the nervous system. Cell. 174:156–171.e16. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Li C, Zhao B, Lin C, Gong Z and An X: TREM2 inhibits inflammatory responses in mouse microglia by suppressing the PI3K/NF-κB signaling. Cell Biol Int. 43:360–372. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Jäkel S, Agirre E, Mendanha Falcão A, van Bruggen D, Lee KW, Knuesel I, Malhotra D, Ffrench-Constant C, Williams A and Castelo-Branco G: Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature. 566:543–547. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kang Z, Wang C, Zepp J, Wu L, Sun K, Zhao J, Chandrasekharan U, DiCorleto PE, Trapp BD, Ransohoff RM and Li X: Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2 + glial cells. Nat Neurosci. 16:1401–1408. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Paintlia MK, Paintlia AS, Singh AK and Singh I: Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis. J Neurochem. 116:508–521. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Romanenko M, Kholin V, Koliada A and Vaiserman A: Nutrition, gut microbiota, and Alzheimer's disease. Front Psychiatry. 12(712673)2021.PubMed/NCBI View Article : Google Scholar | |
|
Bagur MJ, Antonia Murcia M, Jiménez-Monreal AM, Tur JA, Bibiloni MM, Alonso GL and Martínez-Tomé M: Influence of diet in multiple sclerosis: A systematic review. Adv Nutr. 8:463–472. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Mao XY, Yin XX, Guan QW, Xia QX, Yang N, Zhou HH, Liu ZQ and Jin WL: Dietary nutrition for neurological disease therapy: Current status and future directions. Pharmacol Ther. 226(107861)2021.PubMed/NCBI View Article : Google Scholar | |
|
Mao P and Reddy PH: Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta. 1802:66–79. 2010.PubMed/NCBI View Article : Google Scholar | |
|
de Almeida NM, Wessels HJ, de Graaf RM, Ferousi C, Jetten MS, Keltjens JT and Kartal B: Membrane-bound electron transport systems of an anammox bacterium: A complexome analysis. Biochim Biophys Acta. 1857:1694–1704. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T and Tsujimoto Y: Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 434:652–658. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Katz Sand I: The role of diet in multiple sclerosis: Mechanistic connections and current evidence. Curr Nutr Rep. 7:150–160. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Pathak D, Berthet A and Nakamura K: Energy failure: Does it contribute to neurodegeneration? Ann Neurol. 74:506–516. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Lee DH, Gold R and Linker RA: Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: Therapeutic modulation via fumaric acid esters. Int J Mol Sci. 13:11783–11803. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Miller ED, Dziedzic A, Saluk-Bijak J and Bijak M: A review of various antioxidant compounds and their potential utility as complementary therapy in multiple sclerosis. Nutrients. 11(1528)2019.PubMed/NCBI View Article : Google Scholar | |
|
Chen X, Chen R, Guo Z, Li C and Li P: The preparation and stability of the inclusion complex of astaxanthin with β-cyclodextrin. Food Chem. 101:1580–1584. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Kamath BS, Srikanta BM, Dharmesh SM, Sarada R and Ravishankar GA: Ulcer preventive and antioxidative properties of astaxanthin from Haematococcus pluvialis. Eur J Pharmacol. 590:387–395. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Fathi E, Farahzadi R and Charoudeh HN: L-carnitine contributes to enhancement of neurogenesis from mesenchymal stem cells through Wnt/β-catenin and PKA pathway. Exp Biol Med (Maywood). 242:482–486. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhang XS, Zhang X, Wu Q, Li W, Wang CX, Xie GB, Zhou XM, Shi JX and Zhou ML: Astaxanthin offers neuroprotection and reduces neuroinflammation in experimental subarachnoid hemorrhage. J Surg Res. 192:206–213. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Grimmig B, Daly L, Subbarayan M, Hudson C, Williamson R, Nash K and Bickford PC: Astaxanthin is neuroprotective in an aged mouse model of Parkinson's disease. Oncotarget. 9:10388–10401. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Galasso C, Orefice I, Pellone P, Cirino P, Miele R, Ianora A, Brunet C and Sansone C: On the neuroprotective role of astaxanthin: New perspectives? Mar Drugs. 16(247)2018.PubMed/NCBI View Article : Google Scholar | |
|
Speranza L, Pesce M, Patruno A, Franceschelli S, De Lutiis MA, Grilli A and Felaco M: Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target. Mar Drugs. 10:890–899. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Mix E, Meyer-Rienecker H and Zettl UK: Animal models of multiple sclerosis for the development and validation of novel therapies-Potential and limitations. J Neurol. 255 (Suppl 6):S7–S14. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Silvestroff L, Bartucci S, Pasquini J and Franco P: Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination. Exp Neurol. 235:357–367. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Zhen W, Liu A, Lu J, Zhang W, Tattersall D and Wang J: An alternative cuprizone-induced demyelination and remyelination mouse model. ASN Neuro. 9(1759091417725174)2017.PubMed/NCBI View Article : Google Scholar | |
|
Stidworthy MF, Genoud S, Suter U, Mantei N and Franklin RJ: Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol. 13:329–339. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Lotfi A, Soleimani M and Ghasemi N: Astaxanthin reduces demyelination and oligodendrocytes death in a rat model of multiple sclerosis. Cell J. 22:565–571. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Shen P, Lin W, Deng X, Ba X, Han L, Chen Z, Qin K, Huang Y and Tu S: Potential Implications of Quercetin in Autoimmune Diseases. Front Immunol. 12(689044)2021.PubMed/NCBI View Article : Google Scholar | |
|
Tang SM, Deng XT, Zhou J, Li QP, Ge XX and Miao L: Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed Pharmacother. 121(109604)2020.PubMed/NCBI View Article : Google Scholar | |
|
Santangelo R, Silvestrini A and Mancuso C: Ginsenosides, catechins, quercetin and gut microbiota: Current evidence of challenging interactions. Food Chem Toxicol. 123:42–49. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Dower JI, Geleijnse JM, Gijsbers L, Schalkwijk C, Kromhout D and Hollman PC: Supplementation of the pure flavonoids epicatechin and quercetin affects some biomarkers of endothelial dysfunction and inflammation in (Pre)hypertensive adults: A randomized double-blind, placebo-controlled, crossover trial. J Nutr. 145:1459–1463. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Murakami A, Ashida H and Terao J: Multitargeted cancer prevention by quercetin. Cancer Lett. 269:315–325. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Carullo G, Cappello AR, Frattaruolo L, Badolato M, Armentano B and Aiello F: Quercetin and derivatives: Useful tools in inflammation and pain management. Future Med Chem. 9:79–93. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Li G, Shen X, Wei Y, Si X, Deng X and Wang J: Quercetin reduces Streptococcus suis virulence by inhibiting suilysin activity and inflammation. Int Immunopharmacol. 69:71–78. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Ahmed OM, Mohamed T, Moustafa H, Hamdy H, Ahmed RR and Aboud E: Quercetin and low level laser therapy promote wound healing process in diabetic rats via structural reorganization and modulatory effects on inflammation and oxidative stress. Biomed Pharmacother. 101:58–73. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Michalski J, Deinzer A, Stich L, Zinser E, Steinkasserer A and Knippertz I: Quercetin induces an immunoregulatory phenotype in maturing human dendritic cells. Immunobiology. 225(151929)2020.PubMed/NCBI View Article : Google Scholar | |
|
Steinman RM, Hawiger D and Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol. 21:685–711. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Amodio G and Gregori S: Dendritic cells A double-edge sword in autoimmune responses. Front Immunol. 3(233)2012.PubMed/NCBI View Article : Google Scholar | |
|
Saadeldin MK, Abdel-Aziz AK and Abdellatif A: Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Med Hypotheses. 146(110365)2021.PubMed/NCBI View Article : Google Scholar | |
|
Lin W, Wang W, Wang D and Ling W: Quercetin protects against atherosclerosis by inhibiting dendritic cell activation. Mol Nutr Food Res. 61:2017.PubMed/NCBI View Article : Google Scholar | |
|
Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, Wu Y, Mayo L, Ben-Hamo R, Efroni S, et al: IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol. 14:1054–1063. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Wu J and Horuzsko A: Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cells. Hum Immunol. 70:353–356. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Farias AS, Spagnol GS, Bordeaux-Rego P, Oliveira CO, Fontana AG, de Paula RF, Santos MP, Pradella F, Moraes AS, Oliveira EC, et al: Vitamin D3 induces IDO+ tolerogenic DCs and enhances treg, reducing the severity of EAE. CNS Neurosci Ther. 19:269–277. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Iberg CA, Jones A and Hawiger D: Dendritic cells as inducers of peripheral tolerance. Trends Immunol. 38:793–804. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Benson JM and Shepherd DM: Dietary ligands of the aryl hydrocarbon receptor induce anti-inflammatory and immunoregulatory effects on murine dendritic cells. Toxicol Sci. 124:327–338. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Jeuken A, Keser BJ, Khan E, Brouwer A, Koeman J and Denison MS: Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits. J Agric Food Chem. 51:5478–5487. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Hooper LV: You AhR what you eat: Linking diet and immunity. Cell. 147:489–491. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Li Y, Innocentin S, Withers DR, Roberts NA, Gallagher AR, Grigorieva EF, Wilhelm C and Veldhoen M: Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 147:629–640. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Veldhoen M and Brucklacher-Waldert V: Dietary influences on intestinal immunity. Nat Rev Immunol. 12:696–708. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Stockinger B, Di Meglio P, Gialitakis M and Duarte JH: The aryl hydrocarbon receptor: Multitasking in the immune system. Annu Rev Immunol. 32:403–432. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Di Meglio P, Duarte JH, Ahlfors H, Owens ND, Li Y, Villanova F, Tosi I, Hirota K, Nestle FO, Mrowietz U, et al: Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity. 40:989–1001. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y and Kishimoto T: Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA. 107:19961–19966. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kado S, Chang WLW, Chi AN, Wolny M, Shepherd DM and Vogel CFA: Aryl hydrocarbon receptor signaling modifies Toll-like receptor-regulated responses in human dendritic cells. Arch Toxicol. 91:2209–2221. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Stockinger B, Hirota K, Duarte J and Veldhoen M: External influences on the immune system via activation of the aryl hydrocarbon receptor. Semin Immunol. 23:99–105. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Huang RY, Yu YL, Cheng WC, OuYang CN, Fu E and Chu CL: Immunosuppressive Effect of Quercetin on Dendritic Cell Activation and Function. J Immunol. 184:6815–6821. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Nickel T, Hanssen H, Sisic Z, Pfeiler S, Summo C, Schmauss D, Hoster E and Weis M: Immunoregulatory effects of the flavonol quercetin in vitro and in vivo. Eur J Nutr. 50:163–172. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Salehi B, Sharifi-Rad J, Cappellini F, Reiner Z, Zorzan D, Imran M, Sener B, Kilic M, El-Shazly M, Fahmy NM, et al: The Therapeutic potential of anthocyanins: Current approaches based on their molecular mechanism of action. Front Pharmacol. 11(1300)2020.PubMed/NCBI View Article : Google Scholar | |
|
Mohammadi Pour P, Fakhri S, Asgary S, Farzaei MH and Echeverría J: The signaling pathways, and therapeutic targets of antiviral agents: Focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases. Front Pharmacol. 10(1207)2019.PubMed/NCBI View Article : Google Scholar | |
|
Demeilliers C, Toufektsian MC, Salen P, Laporte F, Petroni K and de Lorgeril M: Ethanol drinking, brain mitochondrial DNA, polyunsaturated fatty acids and effects of dietary anthocyanins. Clin Nutr Exp. 12:11–19. 2017. | |
|
Magni G, Marinelli A, Riccio D, Lecca D, Tonelli C, Abbracchio MP, Petroni K and Ceruti S: Purple corn extract as anti-allodynic treatment for trigeminal pain: Role of microglia. Front Cell Neurosci. 12(378)2018.PubMed/NCBI View Article : Google Scholar | |
|
Jomova K and Valko M: Advances in metal-induced oxidative stress and human disease. Toxicology. 383:65–87. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Speciale A, Anwar S, Canali R, Chirafisi J, Saija A, Virgili F and Cimino F: Cyanidin-3-O-glucoside counters the response to TNF-alpha of endothelial cells by activating Nrf2 pathway. Mol Nutr Food Res. 57:1979–1987. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Zhao M, Wang P, Zhu Y, Liu X, Hu X and Chen F: Blueberry anthocyanins extract inhibits acrylamide-induced diverse toxicity in mice by preventing oxidative stress and cytochrome P450 2E1 activation. J Funct Foods. 14:95–101. 2015. | |
|
Yin MC, Wang ZH, Liu WH and Mong MC: Aqueous extract of gynura bicolor attenuated hepatic steatosis, glycative, oxidative, and inflammatory injury induced by chronic ethanol consumption in mice. J Food Sci. 82:2746–2751. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Pham-Huy LA, He H and Pham-Huy C: Free radicals, antioxidants in disease and health. Int J Biomed Sci. 4:89–96. 2008.PubMed/NCBI | |
|
Salehi B, Lopez-Jornet P, Pons-Fuster López E, Calina D, Sharifi-Rad M, Ramírez-Alarcón K, Forman K, Fernández M, Martorell M, Setzer WN, et al: Plant-derived bioactives in oral mucosal lesions: A key emphasis to Curcumin, Lycopene, chamomile, aloe Vera, green tea and coffee properties. Biomolecules. 9(106)2019.PubMed/NCBI View Article : Google Scholar | |
|
Hou DX, Yanagita T, Uto T, Masuzaki S and Fujii M: Anthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: Structure-activity relationship and molecular mechanisms involved. Biochem Pharmacol. 70:417–425. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Theodosis-Nobelos P and Rekka EA: The multiple sclerosis modulatory potential of natural multi-targeting antioxidants. Molecules. 27(8402)2022.PubMed/NCBI View Article : Google Scholar | |
|
Tsuda T, Horio F and Osawa T: Cyanidin 3-O-beta-D-glucoside suppresses nitric oxide production during a zymosan treatment in rats. J Nutr Sci Vitaminol (Tokyo). 48:305–310. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Shah SA, Yoon GH and Kim MO: Protection of the developing brain with anthocyanins against ethanol-induced oxidative stress and neurodegeneration. Mol Neurobiol. 51:1278–1291. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Khan MS, Ali T, Kim MW, Jo MH, Jo MG, Badshah H and Kim MO: Anthocyanins protect against LPS-induced oxidative stress-mediated neuroinflammation and neurodegeneration in the adult mouse cortex. Neurochem Int. 100:1–10. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Aura AM, Martin-Lopez P, O'Leary KA, Williamson G, Oksman-Caldentey KM, Poutanen K and Santos-Buelga C: In vitro metabolism of anthocyanins by human gut microflora. Eur J Nutr. 44:133–142. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Czank C, Cassidy A, Zhang Q, Morrison DJ, Preston T, Kroon PA, Botting NP and Kay CD: Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: A 13C-tracer study. Am J Clin Nutr. 97:995–1003. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Kay CD, Kroon PA and Cassidy A: The bioactivity of dietary anthocyanins is likely to be mediated by their degradation products. Mol Nutr Food Res. 53 (suppl.1):S92–S101. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Afzal O, Dalhat MH, Altamimi ASA, Rasool R, Alzarea SI, Almalki WH, Murtaza BN, Iftikhar S, Nadeem S, Nadeem MS and Kazmi I: Green tea catechins attenuate neurodegenerative diseases and cognitive deficits. Molecules. 27(7604)2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhao T, Li C, Wang S and Song X: Green Tea (Camellia sinensis): A review of its phytochemistry, pharmacology, and toxicology. Molecules. 27(3909)2022.PubMed/NCBI View Article : Google Scholar | |
|
Singh NA, Mandal AK and Khan ZA: Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J. 15(60)2016.PubMed/NCBI View Article : Google Scholar | |
|
Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S and Zipp F: Green tea epigallocatechin-3-gallate mediates T Cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol. 173:5794–5800. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Herges K, Millward JM, Hentschel N, Infante-Duarte C, Aktas O and Zipp F: Neuroprotective effect of combination therapy of Glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PLoS One. 6(e25456)2011.PubMed/NCBI View Article : Google Scholar | |
|
Sun Q, Zheng Y, Zhang X, Hu X, Wang Y, Zhang S, Zhang D and Nie H: Novel immunoregulatory properties of EGCG on reducing inflammation in EAE. Front Biosci (Landmark Ed). 18:332–342. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Grinberg LN, Newmark H, Kitrossky N, Rahamim E, Chevion M and Rachmilewitz EA: Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem Pharmacol. 54:973–978. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Nanjo F, Goto K, Seto R, Suzuki M, Sakai M and Hara Y: Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med. 21:895–902. 1996.PubMed/NCBI View Article : Google Scholar | |
|
van Acker SA, van Den Berg DJ, Tromp MN, Griffioen DH, van Bennekom WP, van der Vijgh WJ and Bast A: Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med. 20:331–342. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P and Rice-Evans CA: Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med. 33:1693–1702. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Zhang B, Rusciano D and Osborne NN: Orally administered epigallocatechin gallate attenuates retinal neuronal death in vivo and light-induced apoptosis in vitro. Brain Res. 1198:141–152. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Solanki I, Parihar P, Mansuri ML and Parihar MS: Flavonoid-based therapies in the early management of neurodegenerative diseases. Adv Nutr. 6:64–72. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Schroeder EK, Kelsey NA, Doyle J, Breed E, Bouchard RJ, Loucks FA, Harbison RA and Linseman DA: Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid Redox Signal. 11:469–480. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Zhang X, Wu M, Lu F, Luo N, He ZP and Yang H: Involvement of α7 nAChR signaling cascade in epigallocatechin gallate suppression of β-Amyloid-Induced apoptotic cortical neuronal insults. Mol Neurobiol. 49:66–77. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Yao C, Zhang J, Liu G, Chen F and Lin Y: Neuroprotection by (-)-epigallocatechin-3-gallate in a rat model of stroke is mediated through inhibition of endoplasmic reticulum stress. Mol Med Rep. 9:69–76. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Han J, Wang M, Jing X, Shi H, Ren M and Lou H: (-)-Epigallocatechin gallate protects against cerebral ischemia-induced oxidative stress via Nrf2/ARE signaling. Neurochem Res. 39:1292–1299. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Abib RT, Peres KC, Barbosa AM, Peres TV, Bernardes A, Zimmermann LM, Quincozes-Santos A, Fiedler HD, Leal RB, Farina M and Gottfried C: Epigallocatechin-3-gallate protects rat brain mitochondria against cadmium-induced damage. Food Chem Toxicol. 49:2618–2623. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Sagi Y, Mandel S, Amit T and Youdim MB: Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis. 25:35–44. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Sutherland BA, Shaw OM, Clarkson AN, Jackson DN, Sammut IA and Appleton I: Neuroprotective effects of (-)-epigallocatechin gallate Following hypoxia-ischemia-induced brain damage: Novel mechanisms of action. FASEB J. 19:258–260. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Koh SH, Lee SM, Kim HY, Lee KY, Lee YJ, Kim HT, Kim J, Kim MH, Hwang MS, Song C, et al: The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett. 395:103–107. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, et al: Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 25:8807–8814. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Ban JY, Jeon SY, Bae K, Song KS and Seong YH: Catechin and epicatechin from Smilacis chinae rhizome protect cultured rat cortical neurons against amyloid beta protein (25-35)-induced neurotoxicity through inhibition of cytosolic calcium elevation. Life Sci. 79:2251–2259. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Reznichenko L, Amit T, Youdim MB and Mandel S: Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J Neurochem. 93:1157–1167. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Pae M, Ren Z, Meydani M, Shang F, Meydani SN and Wu D: Epigallocatechin-3-gallate directly suppresses T cell proliferation through impaired IL-2 utilization and cell cycle progression. J Nutr. 140:1509–1515. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Wu D, Wang J, Pae M and Meydani SN: Green tea EGCG, T cells, and T cell-mediated autoimmune diseases. Mol Aspects Med. 33:107–118. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Information NC for B. PubChem Compound Summary for CID 5280343, Quercetin. [Internet]. 2023 [cited 2023 Apr 26]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/quercetin. | |
|
Mattioli R, Francioso A, Mosca L and Silva P: Anthocyanins: A comprehensive review of their chemical properties and health effects on cardiovascular and neurodegenerative diseases. Molecules. 25(3809)2020.PubMed/NCBI View Article : Google Scholar | |
|
National Center for Biotechnology Information. PubChem Compound Summary for CID 5281224, Astaxanthin. [Internet]. 2023 [cited 2023 Apr 26]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Astaxanthin. | |
|
National Center for Biotechnology Information. PubChem Compound Summary for CID 65064, Epigallocatechin Gallate. [Internet]. 2023 [cited 2023 Apr 26]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Epigallocatechin-Gallate. |
